NOVTU · Novanta Inc
Price & Indicators
The closing range uses available history since Nov 7, 2025; less than a full year is stored.
Up next
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted EPS (Non-GAAP) non-GAAP | $0.89 | Three Months Ended July 3, 2026 | — |
| Adjusted EBITDA non-GAAP | $60.7M | Q2 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 22.8% | Q2 2026 | — |
| Adjusted Gross Margin non-GAAP | 47% | Q2 2026 | — |
| Adjusted Gross Profit (Non-GAAP) non-GAAP | $125.1M | Three Months Ended July 3, 2026 | — |
| Adjusted Gross Profit Margin (Non-GAAP) non-GAAP | 47.1% | Three Months Ended July 3, 2026 | — |
| Adjusted Net Income (Non-GAAP) non-GAAP | $36.53M | Three Months Ended July 3, 2026 | — |
| Adjusted Operating Income (Non-GAAP) non-GAAP | $47.48M | Three Months Ended July 3, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating Income 18.06M
+10.17M Amortization of intangible assets
+4.67M Restructuring costs
+7.83M Acquisition and related costs
+2.2M Planning and design phase of the financial and operation system implementation
+797K Operational transformation costs
+378K EU medical device regulation charges
+3.37M Costs incurred for insurance recovery claim
= Adjusted Operating Income (Non-GAAP) 47.48M
|
|||
| Adjusted Operating Margin (Non-GAAP) non-GAAP | 17.9% | Three Months Ended July 3, 2026 | — |
| Free Cash Flow (Non-GAAP) non-GAAP | $57.47M | Three Months Ended July 3, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net Cash Provided by Operating Activities 64.93M
-7.47M Purchases of property, plant and equipment
= Free Cash Flow (Non-GAAP) 57.47M
|
|||
| Net Debt (Non-GAAP) non-GAAP | -$479.88M | July 3, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Total Debt 229.66M
+9.12M Deferred financing costs
-718.65M Cash and cash equivalents
= Net Debt (Non-GAAP) -479.88M
|
|||
| Organic Revenue Growth non-GAAP | 9.3% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Scientific & Technical Instruments — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NOVTU
this stock
Novanta Inc
|
$4.97B | +5.9% | +35.5% | — | — |
|
KEYS
Keysight Technologies, Inc.
|
$57.18B | +64.5% | +8.0% | 46.0 | 1.4% |
|
GRMN
Garmin Ltd
|
$55.19B | +43.1% | +15.1% | 29.5 | 1.7% |
|
COHR
Coherent Corp.
|
$45.39B | +25.6% | +19.2% | 56.3 | 5.6% |
|
TDY
Teledyne Technologies Inc
|
$28.73B | +23.8% | -4.6% | 30.0 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NOVTU | -5.8% | -4.0% | -1.5% | -4.2% | +5.9% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -4.6% | -3.4% | -9.6% | -5.0% | -6.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.